Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis.

Fan R, Liu Y, Zang G, Li D

Open source

DOI
10.3389/fimmu.2026.1920411
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1920411,
  title = {Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis.},
  author = {Fan R and Liu Y and Zang G and Li D},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1920411},
  url = {https://doi.org/10.3389/fimmu.2026.1920411}
}

RIS

TY  - JOUR
TI  - Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis.
AU  - Fan R
AU  - Liu Y
AU  - Zang G
AU  - Li D
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1920411
UR  - https://doi.org/10.3389/fimmu.2026.1920411
ER  - 

APA

R, F., Y, L., G, Z., & D, L. (2026). Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1920411

Source records